Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | ALT-803 + Bintrafusp alfa + CV301 + NHS-IL12 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ALT-803 | N-803|N803|N 803|nogapendekin alfa|ALT803|ALT 803 | ALT-803 (nogapendekin alfa) is a fusion protein comprising a mutant version of IL-15 with increased activity and IL-15Ra fused to the Fc region of IgG1, which activates CD8+ T-cells and promotes effector activity, potentially resulting in increased antitumor immune response (PMID: 24404427, PMID: 31338557). | ||
Bintrafusp alfa | MSB0011359C|M7824 | Immune Checkpoint Inhibitor 146 PD-L1/PD-1 antibody 107 TGFBR2 Antibody 2 | Bintrafusp alfa is a human PD-L1 (CD274) antibody fused with transforming growth factor-beta (TGF-beta, TGFBR2) receptor II extracellular domain, which blocks two immuno-inhibitory pathways simultaneously, therefore enhances anti-tumor immunity (PMID: 29298798, PMID: 32461347). | |
CV301 | CV-301|PANVAC|CV301-V/F|BN-CV301 | CV301 is a poxvirus-based vaccine that encodes tumor antigens CEA and MUC-1, and 3 costimulatory molecules including B7.1, ICAM-1, and LFA-3, which may stimulate antitumor immune response (PMID: 31110074). | ||
NHS-IL12 | M9241|M-9241 | NHS-IL12 (M9241) is an immunocytokine composed of IL-12 linked to human tumor necrosis factor targeted IgG1, which may result in enhanced anti-tumor immune response (PMID: 24681847). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04491955 | Phase II | ALT-803 + Bintrafusp alfa + CV301 + NHS-IL12 ALT-803 + Bintrafusp alfa + CV301 | Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers | Completed | USA | 0 |